Status:
COMPLETED
Efavirenz in Treating Patients With Metastatic Prostate Cancer
Lead Sponsor:
Institut Bergonié
Conditions:
Prostate Cancer
Eligibility:
MALE
18-120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients ...
Detailed Description
OBJECTIVES: Primary * To assess the effect of efavirenz on the PSA non-progression rate at 3 months in patients with castration-refractory metastatic prostate cancer. Secondary * To assess the eff...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed prostate cancer
- Metastatic disease
- Castration-refractory disease
- No clinical symptoms related to disease progression
- PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 8 2014
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00964002
Start Date
May 1 2008
End Date
April 8 2014
Last Update
May 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Bergonie
Bordeaux, France, 33076